Karyopharm presents updated exploratory subgroup analyses from siendo study in patients with advanced or recurrent tp53 wild-type endometrial cancer during 2024 asco plenary series: rapid abstract updates

Long-term follow-up data signal promising progression-free survival (pfs) for selinexor in the maintenance setting with median pfs of 28.4 months in the tp53 wild-type and 39.5 months in the proficient mismatched repair status (pmmr) tp53 wild-type exploratory subgroups q-twist, an important metric assessing both quality and quantity of clinical benefit, suggests improvement with selinexor versus placebo, which is critical in the maintenance setting company highlights additional presentations in endometrial cancer and myelofibrosis at asco 2024 newton, mass. , june 1, 2024 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory subgroup analyses from the siendo study (nct03555422), in patients with advanced or recurrent tp53 wild-type endometrial cancer at the 2024 american society of clinical oncology (asco) annual meeting.
KPTI Ratings Summary
KPTI Quant Ranking